patients were analyzed. Early change in stroke volume was significantly associated with ENI by logistic regression analysis (OR 0.93, p = 0.048) and remained significant after controlling for stroke size and severity (OR 0.90, p = 0.032). Thus, for every 1 mL increase in stroke volume, there was a 10% decrease in the odds of ENI, while for every 1 mL decrease in stroke volume, there was a 10% increase in the odds of ENI. Neither infarct volume at 24 h nor percent of early reperfusion were significantly associated with ENI by logistic regression. Receiver-operator characteristic analysis identified early change in stroke volume as the only biomarker of the 3 that performed significantly different than chance ( p = 0.03). Conclusions: Early fluctuations in stroke size may represent a more reliable biomarker for response to therapy than the more traditional measures of final infarct volume and percent of early reperfusion.
useful in Phase II clinical trials and in guiding clinical management. Magnetic resonance imaging (MRI) is an established biomarker for delineating areas of infarction with diffusion-weighted imaging (DWI), identifying regional ischemia with perfusion-weighted imaging (PWI), and visualizing vascular occlusion with time-of-flight (TOF) angiography. The volume of restricted water movement detected on DWI 24-48 h after stroke onset, often referred to as the final infarct volume, has been proposed as a biomarker for response to therapy [1] . Another commonly used biomarker for response to therapy is the percent of early reperfusion identified as a reduction in PWI lesion size [2, 3] . A less commonly measured biomarker for response to therapy is the early change in stroke size measured on apparent diffusion coefficient (ADC) maps, immediately before and after treatment. Although it is known that infarct volumes can fluctuate after acute treatment, there is disagreement about the clinical relevance of these changes since decreases in stroke volume are typically transient. We hypothesized that early stroke volume change would provide the earliest prognostic information about response to therapy. The purpose of this study was to compare the biomarker of the change in stroke volume 2 h after treatment with that of the final infarct volume and percent of early reperfusion to predict ENI in stroke patients receiving acute intervention.
Materials and Methods

Patient Population
This study was governed under the guidelines of the Declaration of Helsinki of 1975 (including the revisions in 1983), and written informed consent was obtained from all subjects. Patients consented and enrolled in the NIH Natural History of Stroke Study titled "Evaluation, Pathogenesis, and Treatment of Patients with or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)," during the years of 2013 and 2014 were considered for this study. The institutional review board for the National Institute of Neurological Disorders and Stroke and the 2 enrolling hospitals (Suburban Hospital, Bethesda, Maryland and Medstar Washington Hospital Center, District of Columbia) approved this study. Briefly, the NIH Natural History of Stroke Study is an observational imaging study. The protocol for imaging study patients within the first 24 h is described below. At both sites, the standard practice was to triage all patients with suspected acute ischemic stroke with MRI, provided they do not have a contraindication to MRI. Gadolinium is used for perfusion imaging, provided there are no contraindications to the contrast agent, such as renal dysfunction or contrast allergy. MR angiography (MRA) of the intracranial vessels is also obtained. Patients with an acute ischemic stroke on MRI are eligible for enrollment in the NIH Natural History of Stroke Study, including patients who do not receive gadolinium. During the first 24 h, patients or their legal representative are approached for consent. Patients who consented prior to the 2 h time point undergo an MRI at the stipulated time. Patients remain eligible for enrollment in the study if consent can be obtained prior to the 24 h time point. As a result, only a subset of the total number of patients enrolled into the Natural History of Stroke Study had the imaging necessary to be part of the current analysis as described below.
MRI Parameters
Images were acquired on a 1.5 T GE Signa scanner (General Electric Medical Systems, Milwaukee, WI, USA), a 3 T Philips Achieva scanner (Philips Healthcare, Best, The Netherlands), or a 3 T Siemens Skyra scanner (Siemens AG, Munich, Germany). Image sequences and typical parameter ranges were: diffusion tensor imaging (TR 4,461-10,500 ms, TE 61.6-91.3 ms, 3.5 mm slice thickness, 40 slices) used to generate trace DWI using 3 orthogonal directions (b = 0 and 1,000 s/mm 2 ) and ADC maps; fluid attenuated inversion recovery imaging (TR 9,000 ms, TE 120-145 ms, 3.5 mm slice thickness, 40 slices); TOF MRA images (TR 18-23 ms, TE 3.43-6.8 ms, 0.75-1.4 mm slice thickness, 73-95 slices); gradient recall echo images (TR 700-800 ms, TE 12-20.4 ms, 3.5-7 mm slice thickness, 20-40 slices); dynamic susceptibility contrast PWI (TR 1-1.5 s, TE 25-45 ms, 7 mm slice thickness, 20 slices, 40-80 dynamics), which was collected during the injection of a weightbased dose of gadolinium (0.1 mmol/kg of gadolinium-DPTA, Magnevist; Bayer Schering Pharma, Whippany, New Jersey or gadolinium-BOPTA Multihance, Bracco Diagnostics, Monroe Township, NJ, USA).
Image Processing
The target population for inclusion in this study were patients who presented with a perfusion deficit; this required them to have had PWI with gadolinium as part of their initial MRI. Perfusion deficits were defined on the pretreatment MRI by thresholding the PWI time-to-peak maps at a 4 s delay in contrast arrival, compared to normal tissue from the contralateral hemisphere. This resulted in a region of interest (ROI) which, through co-registration methods, could be moved between image sequences and through imaging time points [4] . This enabled all MRI quantification to be performed in the native space of the scan, not on the co-registered image. Within that ROI, the volume of ADC voxels whose diffusion coefficient was less than 600 mm 2 /s was calculated. Early change in stroke size was measured by subtracting the pretreatment ADC volume from the 2-h ADC volume. For patients with reduction in their ADC volume (negative change) at the 2-h time point, sustained lesion reversal was considered to have occurred if the 24-h ADC volume remained less than or equal to the 2-h ADC volume. Percent of early reperfusion was calculated as the fraction of the pretreatment PWI ROI that was no longer greater than or equal to 4 s on the time-to-peak map of the 2-h MRI. Thus, the percent of early reperfusion at 2 h reflects the degree of recanalization 2 h after acute intervention was administered to the patient. The final infarct volume was calculated by segmenting the ROI superimposed on the 24 h DWI into stroke and non-stroke subgroups using a k-means clustering algorithm. All image processing was done using Matlab software (Mathworks, Natick, MA, USA). The analysis of early change in stroke size was performed in patients with pretreatment and 2 h MRI scans. Comparison of early change in stroke size with percent of reperfusion and final infarct volume was restricted to patients who had the necessary imaging for all 3 biomarkers.
Outcomes
National Institutes of Health Stroke Scales (NIHSS) were assessed at the time of each MRI by neurologists who are certified in performing the NIHSS and undergo NIHSS training annually. ENI was defined as a decrease of 4 or more points on the NIHSS from the pretreatment assessment to the post 24-h assessment. The pretreatment MRI brain and TOF MRA were reviewed by a vascular neurologist (A.N.S.), who was blinded to clinical outcome, for stroke location, and the presence of a large vessel occlusion. Large vessel occlusion was defined as occlusion of the first segment of the middle cerebral artery or occlusion of the distal internal carotid artery. Recanalization status after acute treatment was assessed by measuring the perfusion volumes on the follow-up MRI scans performed 2 and 24 h post thrombolysis. Additionally, a modified Rankin score (mRS) was obtained at 30 and 90 days whenever possible. For the purposes of this study, if the 90 day mRS was not available, then the 30 day mRS was used. A good functional outcome was defined as a mRS of 0 or 1.
Statistics
To evaluate whether each study measurement was significantly different between patients with and without ENI, Fisher's exact test was used for categorical variables and Wilcoxon Rank-Sum test was used for continuous variables. Univariate and multivariate logistic regression models were used to investigate the relationship between the change in early stroke volume as a continuous measurement and a binary outcome of ENI. The OR for the early change in stroke volume and its 95% CI were constructed. Multivariate logistic models were constructed by adding admission NIHSS and pretreatment ADC lesion volume to the univariate model containing just early change in stroke volume.
Furthermore, a receiver operating characteristic (ROC) analysis [5] was performed to compare the performance of the 3 imaging biomarkers (percent of early reperfusion, final infarct volume, and early change in stroke size between the baseline and 2 h MRI) using the subset of patients with adequate data to test all 3 imaging biomarkers. Specifically, the non-parametric area under the ROC curve (AUC) of each imaging biomarker was calculated for its ability to predict ENI. Youden's J statistic was then used to define the optimal cut-point. Specificity and sensitivity were described at that cut-point for early changes in stroke volume.
p values <0.05 were considered significant. All statistical data analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results
During the study period, 131 patients had an MRI prior to treatment with intravenous tPA and were subsequently enrolled into the NIH Natural History of Stroke Study. Of these, 59 patients had the necessary imaging to calculate the early change in stroke volume, 49 had the necessary imaging to calculate the percent of early reperfusion, and 51 had the necessary imaging to calculate the final infarct volume. Of these, data were available to calculate ENI in 58 patients. The reasons for patient exclusions are detailed in Figure 1 .
The demographics for patients with and without ENI are listed in Table 1 . ENI occurred in 25 (43%) patients. The NIHSS on admission was significantly higher in patients with ENI. Patients with ENI also had significantly larger ADC volumes prior to treatment than patients without ENI (6.4 mL [4.2-19.6] vs. 2.6 mL [0.4-9.8], respectively, p value = 0.02). The pretreatment perfusion volumes did not differ between groups ( p = 0.36). In the total population of patients, 33 (57%) had a thrombus visible on the gradient echo image that corresponded with a vascular occlusion on the MRA within either the M2 or M1 segment of the middle cerebral artery or the distal internal carotid artery. The percent of reperfusion 2 h postacute intervention did not differ between groups ( p = 0.27). The percent of reperfusion detected at 24 h also did not reach statistical significance ( p = 0.07). Thus, no clear difference in recanalization was detected between the ENI groups.
The difference between the 2 h ADC volume and the ADC volume at baseline was significantly different between patients with and without ENI (-1. . This indicates that for every 1 mL increase in stroke volume at 2 h, there is a 10% decrease in the odds of ENI, and for every 1 mL decrease in stroke volume at 2 h, there is a 10% increase in the odds of ENI.
Out of the 58 patients analyzed for the early changes in stroke volume and ENI, 33 exhibited a reduction in stroke volume 2 h after treatment. Of these 33 patients, 30 had an evaluable ADC acquired at 24 h. Only 6 (20%) of these patients had sustained lesion reversal at 24 h. For patients with a decrease in the ADC volume at 2 h relative to the baseline ADC volume, but without sustained lesion reversal ( n = 24), the median percent increase in ADC volume at 24 h was 38% [8-61%] . Thus, the clinical improvement found with decreased early stroke volume occurred despite return of a substantial portion of the original lesion in most patients. Two examples of this phenomenon are depicted in Figure 2 . The AUC was higher for early change in stroke volume than for percent of early reperfusion or final infarct volume, and early change in stroke volume was the only imaging biomarker that performed significantly better than AUC of 0.5 (chance), with a p value of 0.03. The sensitivity and specificity of early change in stroke volume using the optimal cut-off were 65 and 86%, respectively. Thus, approximately 14% of patients without ENI using the early changes in stroke volume will be incorrectly identified as having ENI as a false positive.
ENI was used in this study as a marker of response to therapy/acute ischemic stroke treatment, however, modified Rankin scale (mRS) is a typical measure used for assessing the functional outcome in clinical trials. Of the 46 patients in this study with available mRS, 14 (70%) with ENI had a good functional outcome (mRS of 0 or 1) compared to 8 (32%) without ENI ( p value = 0.02). 
Discussion
It is intuitive to think that the size of a patient's stroke would be representative of their response to therapy. In the absence of effective reperfusion, strokes will grow in size. However, there is an anecdotal clinical observation that patients who receive acute stroke treatments, such as intravenous tPA or embolectomy, and appear clinically to respond to therapy, often still have a sizable infarct on their DWI when performed at 24 h. It was this clinical observation that led us to question how good the final infarct volume is as a biomarker for response to therapy.
Using final infarct volume based on the 24 h DWI, as was recently recommended by the STAIR imaging guidelines [1] , the lesion measurement is based on both T2 signal change and restricted diffusion. Thus, the resulting biomarker reflects both cytotoxic and vasogenic edema. When calculating early change in stroke volume based on ADC values during the first 2 h, only changes in diffusion restriction are included in the biomarker. Thus, early change in stroke volume gives a more direct measure of cellular function and injury, and this may account for our findings.
In our study, we found that early change in stroke volume was better than the more commonly used MRI biomarker, final infarct volume, in identifying patients who had responded to therapy clinically. Moreover, we found that in patients with reversal of their ADC lesion, the decrease in volume is rarely sustained, which is in agreement with prior descriptions of this phenomenon [6] [7] [8] [9] . However, unlike prior studies that reported minimal clinical benefit to unsustained lesion reversal [10] [11] [12] , we found that early change in stroke volume was associated with clinical improvement, with patients being 10% more likely to have ENI for every 1 mL decrease in stroke lesion volume from baseline to the 2 h time point. This discrepancy may come from the assumption of prior investigators that the incorporation of transient stroke lesion volumes into the final infarct volume was equivalent to a lack of clinical benefit, or that the clinical improvement occurs secondary to resolution of a perfusion deficit. In our study, the pretreatment perfusion volumes were not different between patients with or , d ) . Notice that at the 2-h time point, for patients with ENI, the ADC lesion has reversed, while for patients without ENI, the ADC lesion persists. By 24 h, both patients show a substantial DWI lesion volume; however, the patient with decreased early change in stroke size has a sustained clinical improvement. ENI, early neurologic improvement; ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; NIHSS, National Institute of Health Stroke Scale. without ENI, and resolution of the perfusion deficit did not perform well in identifying ENI. This may be due to the fact that resolution of the perfusion deficit does not capture the underlying injury. Unlike the perfusion deficit, the ADC volumes were significantly different, with larger volumes in patients with ENI. This may be the reason why the baseline NIHSS were also higher in ENI group. It may be that patients with larger lesions had more potential tissue to salvage (reverse) and thus a higher likelihood for ENI with reperfusion. We opted to use a decrease in NIHSS of 4 or more to delineate ENI. Given that small improvements in NIHSS could be unrelated to thrombolysis, improvement in very mild stroke patients (NIHSS <3) were not included in the ENI group [13] .
The patients in our cohort, and those in other studies with similar findings [6, 7, [14] [15] [16] , were imaged and treated in early time windows. Since early change in stroke volume is closely associated with successful early reperfusion, the benefit of early reduction in stroke lesion volume may not be detected if recanalization and imaging are acquired later. Although it has previously been reported that non-sustained reversal of stroke lesions has clinical benefit [6, 7, 16] , we are the first to compare early changes in stroke lesion volume with the final infarct volume as an imaging biomarker for clinical response to therapy.
One interpretation of our finding is that, when looking at 24-h DWI, not all strokes are the same. Animal data support the hypothesis that the final infarct volume does not capture early pathophysiologic changes. An MRI study of rats undergoing transient middle cerebral artery occlusion found that animals exposed to 30 and 60 min of cerebral ischemia demonstrated transient reversal of the ADC lesion, while animals with 2.5 h did not [17] . This may explain why other human studies have reported less frequent transient reversal than was detected in our study [8] . Hematoxylin and eosin staining of tissue with transient reversal has demonstrated incomplete areas of neuronal cell loss and preservation of astrocytes. Capillaries in areas with transient reversal are less likely to stain for markers of stress than tissue that did not have transient reversal. Tissue in regions of lesion growth or lack of ADC fluctuation is characterized by necrosis and complete infarction [18] . Thus, DWI lesions on an MRI scan 24 h after stroke may represent a heterogeneous population of lesions with varying clinical outcomes that are not best captured by final infarct volume [19] . MRIs collected at 24 h after the event may lack the critical information to determine if there has been a clinical benefit. If this is true, then it is important to consider this when designing clinical trials that are planning to use imaging biomarkers of response to therapy.
The strength of this study is that it was based on a prespecified clinical hypothesis; however, there are several limitations to this study. Our sample size was small, and we do not know if we were powered to rule out an association between response to therapy and final infarct volume; rather, it is more likely that with a larger sample size, a significant association would be identified. Larger studies looking at long-term outcome have found a significant relationship between the final infarct volume and mRS at 90 days [20] . Here we did not directly look at the association of imaging biomarkers with functional outcome (mRS), as the focus was on response to therapy. It is important not to conflate these measures; however, for the 148 population studied, ENI was associated with good functional outcome. Although our study supports the use of early change in stroke volume as a better biomarker for response to therapy, this study alone does not establish superiority over conventional measures such as final infarct volume or percent of early reperfusion. In addition, only patients able to tolerate serial imaging were included in this study, which may have resulted in some selection bias. We used a fully automated pipeline to perform the biomarker measurements. The advantage of this approach is that it is highly reproducible and avoids human bias. However, removing the human component can result in increased noise in the measurements. Additionally, our biomarker definitions may be different than those used in other studies, thus our results may not be comparable to their findings. Imaging of collateral circulation, which may also be a predictor of ENI, was not performed in this study. We also acknowledge that our study findings will need to be further investigated in different patient populations.
This study gives preliminary evidence that early changes in stroke volume should be collected as a biomarker in future clinical trials for which imaging is being used to assess response to therapy. Although MRI is not the standard imaging modality for screening for acute treatment in acute ischemic stroke, it has been successfully utilized at specialized research centers [21] and in previous multicenter clinical trials [3] . Future studies should evaluate these findings in a larger cohort.
